Xavier Montalban Selected Research

Opportunistic Infections (Opportunistic Infection)

11/2019	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
4/2019	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
3/2015	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xavier Montalban Research Topics

Disease

220	Multiple Sclerosis 04/2024 - 02/2002
45	Relapsing-Remitting Multiple Sclerosis 01/2024 - 10/2002
18	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 09/2002
14	Disease Progression 11/2023 - 09/2002
14	Chronic Progressive Multiple Sclerosis 11/2023 - 06/2004
12	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 09/2008
11	Inflammation (Inflammations) 03/2024 - 01/2005
11	Progressive Multifocal Leukoencephalopathy 10/2023 - 02/2012
11	Infections 09/2023 - 02/2010
10	Atrophy 04/2024 - 11/2011
9	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 05/2011
6	COVID-19 04/2024 - 07/2020
6	Neuromyelitis Optica (Devic's Disease) 09/2023 - 05/2013
6	Nervous System Diseases (Neurological Disorders) 01/2021 - 11/2014
6	Neoplasms (Cancer) 01/2020 - 09/2008
4	Herpes Zoster 12/2023 - 02/2010
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 09/2012
4	Stroke (Strokes) 01/2023 - 01/2020
4	Atrioventricular Block 11/2019 - 02/2010
3	Ganglion Cysts (Ganglion) 04/2024 - 07/2019
3	Optic Neuritis (Retrobulbar Neuritis) 04/2024 - 04/2015
3	Chickenpox 12/2023 - 02/2010
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 08/2023 - 12/2002
3	Rheumatoid Arthritis 08/2023 - 10/2020
3	Parkinson Disease (Parkinson's Disease) 01/2023 - 07/2012
3	Epilepsy (Aura) 01/2023 - 01/2021
3	Macular Edema 06/2021 - 02/2010
3	Fatigue 01/2021 - 08/2006
3	Neuroinflammatory Diseases 01/2020 - 01/2017
3	Opportunistic Infections (Opportunistic Infection) 11/2019 - 03/2015
3	Lymphopenia (Lymphocytopenia) 04/2019 - 03/2016
3	Bradycardia 03/2016 - 02/2010
2	Measles 12/2023 - 01/2023
2	Brain Diseases (Brain Disorder) 10/2023 - 08/2002
2	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2021
2	Encephalitis (Encephalitis, Rasmussen) 01/2023 - 01/2020
2	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 01/2023 - 01/2020
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2023 - 01/2021
2	Ulcerative Colitis 10/2020 - 07/2016

Drug/Important Bio-Agent (IBA)

40	Biomarkers (Surrogate Marker)IBA 01/2024 - 08/2006
26	Interferon-betaIBA 01/2024 - 09/2002
24	Natalizumab (Tysabri)FDA Link 04/2024 - 09/2010
18	Fingolimod Hydrochloride (FTY720)FDA Link 09/2023 - 09/2006
17	InterferonsIBA 01/2023 - 10/2002
15	AntibodiesIBA 09/2023 - 07/2003
13	Cladribine FDA LinkGeneric 12/2023 - 09/2018
13	ocrelizumabIBA 10/2023 - 01/2017
12	Proteins (Proteins, Gene)FDA Link 11/2021 - 06/2006
10	TabletsIBA 12/2023 - 09/2018
10	Oligoclonal BandsIBA 11/2022 - 05/2013
10	ChitinasesIBA 11/2021 - 04/2010
9	Myelin-Oligodendrocyte GlycoproteinIBA 04/2024 - 01/2007
9	Immunoglobulin G (IgG)IBA 11/2022 - 12/2002
7	teriflunomideIBA 01/2024 - 11/2016
7	GadoliniumIBA 02/2023 - 02/2003
6	evobrutinibIBA 03/2024 - 01/2019
6	Alemtuzumab (Campath)FDA Link 01/2023 - 07/2012
6	AntigensIBA 01/2023 - 02/2002
6	CytokinesIBA 01/2021 - 08/2010
6	Therapeutic UsesIBA 01/2021 - 05/2008
6	Interferon beta-1a FDA Link 11/2019 - 09/2004
5	ofatumumab FDA Link 06/2022 - 01/2020
5	laquinimodIBA 04/2022 - 03/2012
5	Interferon beta-1b (Betaseron)FDA Link 11/2011 - 06/2004
4	VaccinesIBA 04/2024 - 01/2012
4	Agammaglobulinaemia Tyrosine KinaseIBA 03/2024 - 01/2019
4	InflammasomesIBA 01/2023 - 03/2015
4	Immunoglobulin M (IgM)IBA 06/2022 - 12/2002
4	Monoclonal AntibodiesIBA 01/2022 - 04/2010
4	ozanimodIBA 06/2021 - 11/2019
4	Daclizumab (Zenapax)FDA Link 10/2020 - 04/2010
4	Semaphorins (Semaphorin)IBA 01/2017 - 03/2013
4	AutoantigensIBA 12/2016 - 12/2002
3	Retinaldehyde (Retinal)IBA 04/2024 - 07/2019
3	Messenger RNA (mRNA)IBA 04/2024 - 05/2013
3	AutoantibodiesIBA 01/2023 - 12/2002
3	Dimethyl FumarateIBA 01/2023 - 11/2016
3	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 10/2021
3	Sphingosine-1-Phosphate ReceptorsIBA 06/2021 - 03/2016
3	EnzymesIBA 07/2016 - 02/2010
3	HLA-DRB1 Chains (HLA DRB1)IBA 12/2014 - 09/2006
3	Glatiramer Acetate (Copaxone)FDA Link 07/2013 - 06/2005
3	Immunologic Factors (Immunomodulators)IBA 01/2013 - 02/2012
2	COVID-19 VaccinesIBA 10/2023 - 01/2022
2	Antiviral Agents (Antivirals)IBA 09/2023 - 01/2011
2	Rituximab (Mabthera)FDA Link 09/2023 - 10/2020
2	IronIBA 01/2022 - 01/2022
2	LigandsIBA 11/2021 - 04/2013
2	Interleukin-18 (Interleukin 18)IBA 01/2021 - 03/2015
2	InterleukinsIBA 01/2021 - 10/2017
2	nitazoxanide (NTZ)FDA Link 01/2021 - 08/2017
2	Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)IBA 10/2020 - 01/2019

Therapy/Procedure

53	Therapeutics 04/2024 - 06/2003
4	Injections 09/2023 - 07/2020
4	Cognitive Training 01/2022 - 09/2015
3	Treatment Delay 04/2024 - 07/2013
3	Immunotherapy 01/2022 - 09/2008
3	Immunomodulation 01/2012 - 11/2011
2	Wearable Electronic Devices 12/2023 - 07/2020
2	Aftercare (After-Treatment) 01/2023 - 06/2006